There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vera Therapeutics (VERA – Research Report) and Ocular Therapeutix (OCUL – Research Report) with bullish sentiments.
Ocular Therapeutix (OCUL)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Ocular Therapeutix today and set a price target of $12.00. The company’s shares closed last Thursday at $4.34.
According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of
Ocular Therapeutix has an analyst consensus of Strong Buy, with a price target consensus of $12.00, representing a 190.6% upside. In a report issued on January 18, Piper Sandler also maintained a Buy rating on the stock with a $10.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VERA:
- Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
- 3 Best Stocks to Buy Now, 1/25/2024, According to Top Analysts
- 3 Best Stocks to Buy Now, 1/23/2024, According to Top Analysts
- Vera Therapeutics price target raised to $25 from $22 at JPMorgan
- Vera Therapeutics to host research and development day
